What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy
Toward personalized treatment in Waldenström macroglobulinemia
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
Novel approaches to targeting MYD88 in Waldenström macroglobulinemia
The importance of the genomic landscape in Waldenström’s Macroglobulinemia for targeted therapeutical interventions
Comparative outcomes of immunochemotherapy regimens in Waldenstrom macroglobulinaemia
CXCL13 levels are elevated in patients with Waldenstrom's Macroglobulinemia, and are predictive of major response to ibrutinib
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia
Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
Future therapeutic options for patients with Waldenström macroglobulinemia
Epigenomics in Waldenstrom's macroglobulinaemia
MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia
Guideline for the diagnosis, treatment, and response criteria for Bing Neel Syndrome